New Swiss Medtech Partnership Enhances UK–Switzerland HealthTech Links
Topic : News and Press Type : Press Release
ABHI is pleased to announce that it has entered into a memorandum of understanding (MoU) with Swiss Medtech, Switzerland’s leading medical technology association. This new partnership will strengthen ABHI’s international links with an important geography for high-value HealthTech, while providing a strong partner with an influential voice in wider European discussions.
Switzerland is home to a thriving HealthTech ecosystem, world-leading companies, research institutions and a strong heritage in advanced manufacturing. As a global hub for innovation and investment, and a country that consistently ranks among the top performers in health outcomes, Switzerland represents an important partner market for the UK’s HealthTech community.
Our intention is to work with Swiss Medtech to share intelligence, align on critical issues facing our sector - including regulation, sustainability initiatives, and trade - and identify opportunities for collaboration between our memberships. Together, we will also pursue joint advocacy to ensure that the updated UK–Switzerland Free Trade Agreement includes comprehensive, high-standard provisions for HealthTech, and develop shared policy positions relating to trade between the UK, Switzerland and the EU.
Adrian Hunn, Managing Director of Swiss Medtech, said: “This agreement deepens collaboration between our two associations at a time of real opportunity for HealthTech. By working together, we can strengthen our collective voice in European and global discussions, shape policies that support innovation and trade, and ensure the UK and Switzerland remain at the forefront of delivering advanced technologies to patients.”
Peter Ellingworth, CEO, ABHI, added: “As sovereign third countries, the UK and Switzerland share many common priorities, and this partnership offers significant opportunities to collaborate on issues that are critical to our domestic industries. From regulatory alignment and sustainability, to advancing women’s health and other pressing healthcare challenges, we have much to learn from one another. This collaboration will amplify our global influence and strengthen our respective markets, advancing innovation and expanding patient access.”
We look forward to sharing further details and opportunities as we bring this partnership to life.
L - R: Adrian Hunn, Phil Kennedy & Peter Ellingworth